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In order to investigate possible synergistic influences of different mtDNA mutations on penetrance and severity of L&r’s hereditary optic 
neuropathy (LHON), a large German LHON pedigree is characterized with respect to 10 different mutations associated with LHON. All members 
of the family carry three diffcrcnt mtDNA mutations (at nucleolide 4,216, 11,775 and 13.708) in a homoplasmic form, rcgardlcss of whether or 
not they are clinically affected. Testing for another 7 mutations reveals negative results in all family members, Hence, the variable disease xpression 
of the family members cannot be explained by varying combinations of LHON-associated mtDNA mutations. 
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1. INTRODUCTION 
The maternally transmitted Leber’s hereditary optic 
neuropaihy (LI-ION) leads to bilateral :OSS of central 
vision as a result of optic nerve death [l]. The disease 
is associated with defined mutations of the mitochon- 
drial DNA (mtDNA) [2]. About 50-80% of LHON pa- 
tients can be attributed to a G-to-A transition mutation 
at position 11,778 in the ND4 subunit gene of complex 
I of the respiratory chain [3]. For the remainder of the 
LHON patients not carrying this mutation several other 
mutations have been described [2]. In LHON families, 
usually both clinically affected and unaffected family 
members carry the mt genetical defect. Therefore the 
question arises, what regulates the penetrance of the 
disease? Since in most sporadic LHON cases, as well as 
in LHON pedigrees, various but distinct mtDNA muta- 
tions [4] have been described, it was suggested that no 
particular mutation, but rather a cluster of synergisti- 
cally interacting mutations may define the apparently 
variable expression of the disease. This assumption was 
confirmed recently by observations in a large LHON 
pedigree from Queensland [T]. While all members of this 
family carry a ND1 gene mutation, one clinically less 
severely affected branch of this pedigree exhibits an 
additional second mutation. To investigate the possibil- 
ity of synergistically interacting mtDNA mutations we 
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respect o 10 different mutational sites reported as being 
associated with LHON (Fig. 1). This was done by re- 
striction fragment analysis and by use of allele-specific 
point mutation primers. 
2. MATERIALS AND METHODS 
The pedigree of the German LHON family is given in Fig. 2. 
2.2. Analysis ofmtDN.4 
Total DNA was extracted from IO ml EDT&blood 15 described [4] 
using standard proteinnse K procedures. Point mutation priming and 
restriction analysis for the different mtDNA positions to be hvesti- 
Sated were performed as follows: PCR amplification was done with 
allele-specific mismatch primers (Table I). These primers produce am- 
plified fragnmnts only in the presence of mutated rntDNA. To conSrrn 
the results, fragments amplified by PCR using the pruner combina- 
tions given in Table II were cut by the respective restriction cndonu- 
cleases. Samples prepared by both methods were visualized in 1% 
agrosc gels containing ethidium bromide. 
3. RESULTS 
Corrvsponderm~ u&m: K.-D. Gerbitz. Institute fur Kiinische 
Chemie und Diabetesforschung, St!~dt. Krankcnhaus MUnchen- 
SchwabinS, K6lner Platz 1, 8000 Uunchcn 40, Germany. Fax: (49) 
(89) 300 8614. 
ribbF~kJlio/~s: bp, b&it p&h; nt, nttdeotidti; LHDN, tibcr’s hCiC%- 
trlry optic ncuropathy; ND, complex I = mhochondrial NADH dehy- 
drogcnase (EC 1.6.99.3). 
All 10 members of the LHON family under study 
carry three different mtDNA mutations (Fig. 3). First, 
the most common mutation, G-to-A, at position 1 I,778 
in the ND4 gene, which eliminates a SfiNl restriction 
site and creates a new one for the endonucleasc, MaeIII. 
The mutation replaces a highly conserved arginine by 
a histidine at position 340 in the ND4 subunit of com- 
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tlurnan mt DNA 
Cytochrome c oxidase I 
Cytochroms c oxi 
A A&. 1. ~OKIL mutations of the mtDNA associated with LHON. Black regions indicate genes on the heavy (outer circle) nnd the light (inner circle) 
strand; tRNA genes are marked by solid lines with the rcspcctivc amino acid abbrcviotions. O,.,, OL, PI+ PL are the respective origins of replication 
and the promotorv for the heavy and light strands. LHON mutation base substitutions are shown outside the double stranded mt genomc with 
the respective nucleotide positions. 
plex I of the respiratory chain. The second mutation u’as 
found at position 13,708 (G-to-A) in the ND5 subunit 
gene. As the restriction sites of the two endonucleases, 
BstNI and Fnu4M1, overlap at position 13,705, the mu- 
tation can be detected by failure of both enzymes to 
cleave the 450 nucleotide (nt) product. The mutation 
_L 
v ‘!d’ 
Fig. 2. Pedigree of the LHON family. Numhrs represent he years or birth; ‘casts investigated in this study. 
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Table I 
PCR rximers and restriction cndonucleascs 
Mutation 
(gene) 
3,4GO 
(ND11 
4,136 
(ND11 
4,216 
(~:I? iD2) 
5,244 
OVD2) 
7,444 
(COX I) 
11,778 
(NW 
13,708 
05) 
15,257 
5’ primer 3’ primer 
(fragment length) 
3,275- 3,304 3,945- 3,91B 
(671 nt) 
3,275- 3,304 5,872- 5.84 
(2598 nt) 
3,275- 3,304 5,872- 5,844 
(2598 nt) 
4,7O4- 4,730 5,132- 5,103 
(429 nt) 
4,808- 4,835 5,461- 5,434 
(654 nt) 
7,172- 7,199 7,8 II- 7,788 
(646 nt) 
11,576-11,602 12,136-12,110 
(561 nt) 
13,570-I 3,595 14,019-13,990 
(450 nt) 
l&015-15,042 15,952-15,925 
(938 nt) 
15,260-l 5,287 16,158-16,131 
(899 nt) 
Restriction cnclonuclease W M 
- 
BsaHI + 
NIUIII + 
NlalIl + 
hfud c 
HpaII + 
(5,242) 
Xl!kzI + 
SfuNI + 
IVfUirrrLIi + 
BsrNI f 
Fnu4HI + 
AccI .t. 
(15,255) 
R%zI + 
W, wild type; M, mutation; +, restriction site present; -, restriction site lost. 
changes a non-polar hydrophobic alanine to a hydro- 
phiiic iliixoike at position 4% in the ND5 subtmit. The 
third mutation found in all LHON family members was 
a T-to-C transition at position 4,216 in the ND1 subunit 
gene. It creates a new restriction site for the endonu- 
clease, NlaIII, and results in a tyrosine/histidine x- 
change in the ND1 gene product. 
All except one of the tested members of our LHON 
family carry these three mutations in a homoplasmic 
for.rn, ix. restriction digests of the amp!ified fragments 
only showed the mutation patterns. The only exception 
is patient III/9 who shows two bands after SfuN 1 diges- 
tion, indicating a heteroplasmic 11,775 mutation (Fig. 
3a). Testing for another 7 mutations listed in Tables 1 
and II produced negative results with both methods in 
all family members. 
Table II 
LHON allele-specific mismatch primers 
Positions Primer scaucnce 
3.438- 3.4(io 
4,182- 4.216 
4,588- 4,317 
5,223- T.244 
S’-G CTA CTA CAA CCC TTC GCT AAC A-3’ 
0 Q 
5’-CTT CCT ACC ACT CAC CCT AGC ATT ACT TAT AAG AC-3’ 
T T 
5’-CA ATC ATA TAC CAA ATC TCT CCC TCA ATA G-3’ 
c A 
5’4GA GGC CTG CCC CCG CTA GCC A- 3’ 
A G 
5’-ACA CAT TCG AAG AAC CCG TAT ACA TAA AAT ATA A-3’ 
c G 
11,745-G 5’-C TCA AAC ‘TAC GAA CGC ACT CAC ACT CA-3’ 
Q 0 
13.680-m 5’-C ACC CTA CTA AAC CCC ATT AAA GGC GTG A-3’ 
C! G 
15,231-u 9’-AA TGA ATC TGA GGA GGC TAC TCA ATA A- 3’ 
G Q 
5’.-TTT ACC ATC ATT GGA CAA GTA GCA GCC A-3’ 
T 4 
The mutation site is underlined. Wild-type nuclcotidcs are given under the primer scqucncc. 
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Fig. 3. Detection of LMON mutations by electrophorcsis of PCR fragments amplified from blood. LHON family (lanes l-10) and controls (lanes 
1 I-16). M, marker ladder. (a) Detection of mutation G+A at nt 11,778: the amplification products resulting from the use of the primers given 
in Table I were digested with §‘NI. All tcstcd LHON family members how the undigested 535 bp fragment, i dicating the absence of the restriction 
site and the presence of the mutation. Control samples arc cut into a 321 bp and 214 bp fragment, respcctivcly. indicating the presence of the 
restriction site and the absence of the mutation. (b) Detection of the mutation G+A at nt 13,705 by use of the allele-specific mismatch primer given 
in Table I. All LHON family members how the 311 bp band, indicating the presence of the mutation. No band is delectable in the controls. 
(c) Detection of mutation T-& at nt 4,216. The amplification products resolting from the USC of the primers given in Table II were digested with 
Nlulll. All controls, except control 13, show the wild-type pattern consisting of the 738, 687, 527, 318, 287 nnd 40 bp fragmsnts. The mutation 
produces an additional cleavage situ within the 738 bp fragment which is consequently cut into a double band of 3741364 bp. This pattern is found 
in all LHON family members as well as in control 13, indicating the presence of the mutation, while all other controls are ncgativc for the mutation. 
As there is no further band detccmble, we can also exclude the presence of the A+G mutation at nt 4,136 in all samples. 
4. DISCUSSION 
Variable penetrance is observed in almost 211. LMON 
pedigrees. The reason for this fact, however, remains 
unknown. Furthermore, the time of onset of LHON 
differs intrafamilially. To follow the idea that interact- 
ing LHON mtDNA point mutations [4,5] would per- 
haps explain some of these variations, we have investi- 
gated a German LHON family with respect o the 10 
LHON-associated mutations reported so far [2]. All 10 
family members under study carry the same LHON 
point mutation pattern independently of whether or not 
they are clinically affected. They are positive for the 
mutations at nt 4,216, 11,778 and 13,708, as well as 
-*-.-r:.., ,,~&Xrrr~ I”, .**r II1YIHLAYI.S H. ..L c..- *I..- m..+n*:nn .a* n* 3,468, 4,917, 5,244, 
7,444, 15,257 and 15,812, thus resembling single cases 
reported by Johns and Berman [9]. The intrafamilial 
variation of disease onset in our family is, for instance, 
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demonstrated by patients III/4 and IV/S. While the first 
does not show any symptoms of the disease at the age 
of 54, the latter had already developed partial optic 
atrophy at the age of 15. Thus there is no evidence at 
present hat a varying pattern of known LHON-associ- 
ated point mutations is responsible for the variable 
manifestation of the disease, at least in this family. 
There is also no evidence for a correlation between the 
age of onset and varying proportions of mutated 
mtDNA, since all examined family members, except he 
affected member 111/9, bear the mutations in homoplas- 
mic form, i.e. only mutated ~LDNA is present. It still 
remains to be discovered what additional mitochon- 
drial, nuclear or environmental factors regulate the ex- 
pression of the genetic defecl as a clinical disorder. 
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